Thanks to your support of The Pink Ribbon Project, a Canadian Cancer Society-supported clinical trial found that 7 in 10 women diagnosed with a specific and common type of early stage breast cancer do not need chemotherapy in addition to hormone therapy.
Over 10,000 women with early stage breast cancer took part in the study. Until now, it wasn’t clear whether chemotherapy offered any added benefit for these women. The trial looked at whether some of them could safely skip chemotherapy.
The results found that genetic testing could accurately predict which women required chemotherapy and which could avoid it altogether without affecting their chances of survival. This discovery could spare thousands of women from chemotherapy-related side effects without impacting the effectiveness of their treatment.
It’s a breakthrough that you helped make possible – one that will forever change the future of breast cancer treatment. Thank you for helping to bring this transformational discovery to life.